Abstract
Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Results: Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. Conclusion: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.
| Original language | English |
|---|---|
| Pages (from-to) | 235-243 |
| Number of pages | 9 |
| Journal | Immunotherapy |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Mar 2020 |
| Externally published | Yes |
Keywords
- immune checkpoint inhibitors
- metastatic
- nivolumab
- non-small-cell lung cancer
- pembrolizumab
- treatment beyond progression
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
